Home » Newsletters » BioWorld Science

BioWorld Science

May 24, 2011

View Archived Issues

Researchers describe discovery and development of hepatitis C treatment GS-5885

Scientists present two new agents against herpes simplex virus

FDA approves use of Edurant in treatment-naive adults with HIV-1

PMX-30063 shows activity against oral mucositis in animal study

PRM-151 is safe and active in healthy volunteers and in subjects with idiopathic pulmonary fibrosis

PF-4357415 is superior to fluticasone propionate in rat model of lung inflammation

Phase II data disclosed on tanezumab in chronic prostatitis/chronic pelvic pain syndrome

First patients enrolled in phase I trial of Glycotope's FSH-GEX

Thermo Fisher Scientific signs definitive agreement to acquire Phadia

Novartis confirms new divisional structure following merger with Alcon

Themis Bioscience raises funds to advance vaccine candidates

New delta opioid receptor antagonists reported by Janssen group

KIST presents novel protein kinase inhibitors for cancer

Merck & Co. describes new phosphodiesterase 10A inhibitors

New closthioamides presented

Scientists prepare new adenosine A2A receptor antagonists

Sosei launches NorLevo emergency contraceptive pill in Japan

FDA approves Incivek for genotype 1 chronic hepatitis C

Nexavar plus standard chemotherapy improves progression-free survival of patients with breast cancer

Genentech reports phase II data on MetMAb/Tarceva in NSCLC

Gactiv approved in Japan for type 2 diabetes in combination with alpha-glucosidase inhibitors

VivaGel is efficacious in phase II trial in bacterial vaginosis

Abbott to submit ALK FISH test for approval in Japan and U.S.

Daiichi Sankyo and AstraZeneca enter copromotion agreement for denosumab in Japan

EMA's CHMP recommends label extension for tocilizumab

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...